Floatz logo

Tozinameran

Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population

Chimei Medical CentervaccineActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
University of California, San Francisco
Phase 2CCC
Enzalutamide
University of California, San Francisco
Phase 2CCC
Indocyanine Green
Oxford University Hospitals NHS Trust
Phase 1/2CCC
MODERNA COVID-19 VACCINE RNA
Chimei Medical Center
D
OXFORD-ASTRAZENECA COVID VACCINE
Chimei Medical Center
D
Carbon Nanoparticle Suspension
The First Affiliated Hospital with Nanjing Medical University
N/ANR

Same molecule, other indications

Tozinameran is also rated in:

systemic lupus erythematosusDormant
CCC
Indicative ·
50 / 100
View asset →
pemphigus vulgarisDormant
CCC
Indicative ·
50 / 100
View asset →
rheumatoid arthritisDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →